Histologix as a GLP/GCP accredited company is compliant with all the relevant guidelines associated with undertaking regulatory preclinical safety assessments which are likely to form part of regulatory submissions as well as the handling, of patient samples from clinical trials.
Histologix’ quality assurance programme is mainly processed based for which we undergo quarterly internal QA audits, however we also undertake study specific audits on request.
The MHRA inspect Histologix at 2 yearly intervals with the initial inspection being held in 2005 where accreditation was granted and this was retained following subsequent inspection in 2007, 2010, 2012, 2015 and 2016.
Histologix provides the Pharmaceutical and Biotechnology industry with specialist pathology services to assist drug development programmes ranging from Discovery, regulatory preclinical safety testing through to clinical trials and include human tissue sourcing, histology, medical and veterinary histopathology, immunohistochemistry, digital pathology and image analysis. These are technologies that have been developed with to meet current and future requirements of targeted therapy.
Through inward investment the services provided by Histologix Ltd use a range of highly sophisticated technologies and platforms aimed at standardising the various processes involved in order to achieve data generation that is consistent, accurate and reproducible and will assist our clients in the development of their drug programmes.
Histologix is a privately owned contract research organisation that provides specialist pathology services for the Pharmaceutical and Biotechnology industry. Set up in 2005 by industry specialists, Histologix is a GLP/GCP accredited, HTA-licenced company with an extensive and impressive track record of successfully delivering a range of IHC/ISH assays to large and small Pharma/Biotechnology companies and is a preferred supplier of these services to a number of companies.
Find out which conference Histologix is exhibiting at, updated news issues and current vacancies.